Compare Altria Group Inc (MO) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Revvity Inc — how do they compare? Altria Group Inc trades at $71.28 (market cap $119.25B), while Revvity Inc trades at $152.05 (market cap $16.98B). The key difference: Altria Group Inc is far larger — about 7× Revvity Inc's market cap, and Altria Group Inc pays the higher dividend (6.22%). Which is the better fit depends on your goals — on Pluang, investors hold Altria Group Inc for 154 Days and Revvity Inc for 12 Days on average.
| MO | RVTY | |
|---|---|---|
Market Cap | $119.25B | $16.98B |
Volume | 11,178,169 | 1,456,900 |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $157.36 |
52-Week Low | $54.72 | $82.26 |
Typical Hold Time | 154 Days | 12 Days |
Enterprise Value | $141.46B | $19.30B |
Dividend Yield | 6.22% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $69.39, up 1.22% today, near the analyst consensus price target of $69.71. The stock shows a bullish technical trend with strong moving average signals, while oscillators remain neutral. Fundamentally, the company maintains robust profitability with a 39% net income margin and strong cash flow, though revenue has been slightly declining. Recent earnings have been mixed, with one beat and two misses in the last three quarters. A high dividend yield of approximately 6.6% is supported by 60 consecutive annual increases, but the balance sheet shows negative shareholder equity.
The outlook for MO balances income appeal against structural challenges. The high dividend and bullish analyst consensus (61.5% buy ratings) offer value for income investors, but risks include declining core tobacco sales, regulatory pressures on nicotine products, and a leveraged balance sheet. Earnings growth and smoke-free product adoption are critical for sustained performance.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
